Entera Bio (NASDAQ:ENTX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock.

Entera Bio Price Performance

ENTX stock opened at $1.70 on Monday. The company has a market cap of $60.83 million, a P/E ratio of -6.54 and a beta of 1.58. Entera Bio has a 1 year low of $0.52 and a 1 year high of $3.35. The stock’s fifty day moving average price is $1.87 and its 200-day moving average price is $1.92.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. As a group, analysts expect that Entera Bio will post -0.23 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 47,328 shares of the company’s stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned 0.13% of Entera Bio as of its most recent SEC filing. 14.11% of the stock is owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.